The Vancouver-based biotech said its net loss for 2025 was roughly US$146 million compared to nearly US$163 million in 2024. Meanwhile, its revenue grew nearly 160 per cent from about US$29 million in 2024 to roughly US$75 million in 2025. (The Logic)
Talking point: Much of the firm’s revenue came in the fourth quarter from a settlement payment after it resolved patent litigation with Bruker Corporation, which saw the Mass.-based firm pay AbCellera US$36 million upfront and future royalty payments. CEO Carl Hansen said in a statement that AbCellera has “transitioned to a clinical-stage biotech” as it moved two of its drugs into clinical trials, including ABCL635. It’s the first drug that the company has discovered for itself, as opposed to with a partner, to move into human trials. AbCellera has been focusing on developing its own pipeline of drugs, seeing it as a more profitable route than relying on royalties from partner-fuelled discoveries.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.